Northrop Grumman Corporation
NOC
$527.39
+1.62%
Northrop Grumman Corporation is a diversified global aerospace and defense prime contractor operating across four reporting segments — Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems — producing platforms and payloads ranging from the B-21 Raider stealth bomber, Global Hawk autonomous aircraft, and F-35 fuselage work to missile defense interceptors, radar and electronic warfare suites, and national-security satellites. As one of only a handful of U.S. primes capable of integrating classified, large-scale 'system-of-systems' programs, Northrop occupies a structurally privileged position in the defense industrial base, with roughly $77.5 billion in market capitalization and approximately 95,000 employees. The current investor debate centers on a stark divergence between the company's strategic franchise — anchored by the B-21 production ramp, the Sentinel intercontinental ballistic missile program, and the Pentagon's accelerating pivot toward AI-enabled autonomous systems — and a stock that has materially underperformed both the market and defense peers over the past year. Sentiment has been pressured by program-level cost charges, working-capital volatility, and a market narrative that favors pure-play space and drone names over legacy primes, even as geopolitical flashpoints (U.S.-Iran strikes, rare-earth supply-chain mandates, and Golden Dome missile-defense funding) reinforce the long-term demand backdrop.…
NOC
Northrop Grumman Corporation
$527.39
Related headlines
Investment Opinion: Should I buy NOC Today?
The synthesized recommendation is Hold, with a bias toward accumulating on weakness for patient investors. The core thesis is that Northrop's strategic franchise — anchored by the B-21, Sentinel, and space systems — is undervalued at 17.05x forward earnings, but near-term execution risks and cash-flow volatility justify waiting for evidence of a turnaround. The analyst consensus rating of 'buy' (mean 2.04) and average target price of $648.05 imply 24.9% upside, but the wide target range ($538–$815) and lack of recent upgrades suggest conviction is moderate.
Supporting evidence includes the forward PE of 17.05x, which is below the trailing PE of 19.57x and near the low end of the historical band (13.5x–38.4x). Revenue growth of 4.36% YoY in Q1 2026 is modest but positive, and profitability remains solid with a 9.97% net margin and 25.08% ROE. TTM free cash flow of $3.305 billion provides a 4.0% FCF yield, and the 1.58% dividend yield with a 30.9% payout ratio is sustainable. The implied upside to the consensus target of $648.05 is 24.9%, and the stock trades at a discount to its own Q1 2026 PE of 27.7x.
The biggest risks that could invalidate the thesis are a failure to convert H2 working capital into cash (Q1 FCF was -$1.823 billion), continued gross margin compression below 19.8%, and a breakdown below the 52-week low of $479.02. The rating would upgrade to Buy if forward PE compresses below 15x or if H2 free cash flow exceeds $3 billion, and downgrade to Sell if revenue growth decelerates below 3% or if gross margin falls below 18%. Relative to its history and peers, NOC appears undervalued on forward earnings but fairly valued on trailing metrics, with the market pricing in skepticism about near-term earnings delivery.
Sign up to view all
NOC 12-Month Price Forecast
Northrop Grumman presents a balanced risk/reward profile at current levels, with the stock trading near 52-week lows but offering a 24.9% upside to the consensus target of $648.05. The valuation is undemanding at 17.05x forward earnings, but near-term execution risks, including margin compression and volatile cash flow, justify a neutral stance. The key catalyst will be H2 2026 free cash flow; if it exceeds $3 billion, the stock could re-rate toward the bull case, but a failure to deliver would likely push shares below the 52-week low of $479.02. I would upgrade to bullish if gross margin stabilizes above 20% and H2 FCF exceeds $3 billion, and downgrade to bearish if revenue growth falls below 3% or if program charges materialize.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Northrop Grumman Corporation's 12-month outlook, with a consensus price target around $648.05 and implied upside of +22.9% versus the current price.
Average Target
$648.05
0 analysts
Implied Upside
+22.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$538 - $815
Analyst target range
Coverage is broad and constructive: 21 analysts cover Northrop Grumman, with a consensus recommendation of 'buy' (recommendation mean of 2.04 on a scale where lower is more bullish) and an average target price of $648.05. Against the current price of $518.97, that implies roughly +24.9% upside to the consensus target, a wide gap that reflects how far the shares have fallen below where the sell side models fair value. The consensus leans bullish, but the recent institutional ratings flow is more muted — Goldman Sachs and TD Cowen reiterated Neutral/Hold in mid-July 2026, Jefferies stayed at Hold in late June, while Citigroup, UBS, Morgan Stanley, and BTIG maintained Buy/Overweight ratings in April. The pattern is one of stable-to-cautiously-positive ratings with no visible downgrades, but also no fresh upgrades to catalyze a re-rating.
The target range is wide, from a low of $538.00 to a high of $815.00 — a spread of $277, or roughly 53% of the current price — which signals meaningful disagreement about the earnings trajectory. The low target of $538 sits only about 3.7% above the current price and effectively prices in continued margin compression, program charges, and a market that keeps awarding defense primes a below-market multiple. The high target of $815 implies roughly 57% upside and would require both multiple expansion back toward the upper end of the historical PE band and successful execution on the B-21, Sentinel, and space franchises, plus a resolution of the working-capital drag that has made quarterly free cash flow so volatile. With consensus estimated revenue of $55.37 billion and estimated EPS of $37.82, the bull case is fundamentally about converting a record backlog into cash rather than about revenue acceleration; the wide spread and the absence of recent upgrades suggest conviction is moderate, and investors should treat the $648 average target as a fair-value anchor rather than a near-term price objective.
Bulls vs Bears: NOC Investment Factors
The bear case currently has stronger evidence, driven by accelerating relative underperformance (-27.20 percentage points vs. SPY over 1 year), margin compression (gross margin down from 21.37% to 19.84%), and a weak balance sheet (current ratio 1.09, Q1 FCF -$1.823 billion). However, the bull case rests on a compelling valuation disconnect: at 19.57x trailing PE and 17.05x forward PE, NOC trades near the low end of its historical range while analyst consensus targets $648.05, implying 24.9% upside. The single most important tension is whether the H2 cash conversion repeats 2025's pattern (Q4 2025 generated $3.235 billion FCF) and validates the full-year cash thesis, or whether program charges and working-capital volatility persist. If H2 cash flow disappoints, the stock likely breaks its 52-week low; if it delivers, the current discount to peers and history should narrow.
Bullish
- Analyst consensus implies 24.9% upside: 21 analysts cover NOC with a consensus 'buy' rating (mean 2.04) and an average target price of $648.05, which is 24.9% above the current $518.97. The low target of $538 is still 3.7% above the current price, suggesting even the most cautious analyst sees limited downside from here.
- Valuation near historical lows: At 19.57x trailing PE and 1.95x PS, NOC trades in the middle-to-lower portion of its own historical range, well below the Q1 2026 reading of 27.7x PE and 9.81x PS. Forward PE of 17.05x represents a 13% compression from trailing, implying the market expects EPS growth.
- Strong profitability and ROE: Trailing net margin of 9.97% and operating margin of 10.20% are healthy for a defense prime, and ROE of 25.08% is exceptional. Q1 2026 net income of $875 million on $9.88 billion revenue demonstrates solid earnings power despite margin pressure.
- Strategic franchise with multi-decade backlog: Northrop is one of only a handful of U.S. primes capable of integrating classified, large-scale 'system-of-systems' programs, anchored by the B-21 Raider, Sentinel ICBM, and space franchises. The Pentagon's AI pivot and Golden Dome missile-defense funding reinforce long-term demand.
Bearish
- Severe relative underperformance: NOC is down 10.98% over the trailing twelve months versus a 16.22% gain for SPY, a relative-strength deficit of 27.20 percentage points. The 6-month change of -29.27% and 1-month change of -10.11% show selling pressure is accelerating, not abating.
- Margin compression and earnings volatility: Gross margin has slipped from 21.37% in Q3 2025 to 19.84% in Q1 2026, and net margin fell from 12.18% in Q4 2025 to 8.86% in Q1 2026. The PEG ratio of 7.41 signals that trailing earnings growth is far too slow to justify even a high-teens PE.
- Weak balance sheet and cash burn: Debt-to-equity of 1.18x and a current ratio of just 1.09 leave limited liquidity cushion. Q1 2026 free cash flow was -$1.823 billion due to a $3.077 billion working-capital outflow, and cash fell from $4.403 billion to $2.090 billion in the quarter.
- Decelerating revenue growth: Q1 2026 revenue grew only 4.36% YoY to $9.881 billion, a sharp deceleration from the 13.1% YoY growth implied by Q4 2025. The modest consolidated growth suggests the B-21 and space ramps are not yet overwhelming program headwinds elsewhere.
NOC Technical Analysis
Northrop Grumman is in a sustained downtrend, with the shares down 10.98% over the trailing twelve months versus a 16.22% gain for SPY — a relative-strength deficit of 27.20 percentage points. At $518.97, the stock sits at roughly 13.2% of its 52-week range of $479.02–$774.00, meaning it is trading in the bottom sixth of its annual band and just 8.3% above its 52-week low. That positioning is characteristic of a falling-knife setup rather than a value opportunity: the stock has lost more than a third of its value from its high (max drawdown of -35.42%), and there is no evidence yet of a durable base, so investors are being paid to wait only if the fundamental thesis holds.
Short-term momentum is deteriorating rather than stabilizing. The 1-month change of -10.11% is worse than the 3-month change of -5.70%, which in turn is worse than the 1-year change of -10.98%, indicating that selling pressure has accelerated into the most recent month rather than abated. The 6-month change of -29.27% confirms the bulk of the damage occurred in the spring and summer, and the 1-month relative strength versus SPY of -9.05 shows the underperformance is idiosyncratic, not merely market beta — SPY fell only 1.06% over the same month. With volume of roughly 588,000 shares and a short ratio of 3.63 days, positioning is not crowded on the short side, but the persistent lower-highs pattern since the April breakdown argues that rallies are being sold.
Key technical levels are well defined. Support rests at the 52-week low of $479.02, roughly 7.7% below the current price; a decisive breakdown there would open a new leg lower and likely force further de-risking by momentum and quant funds. Resistance is the 52-week high of $774.00, some 49.1% above the current price, with intermediate supply likely clustered around the $550–$590 area where the stock repeatedly failed in July and August. Notably, the reported beta of -0.11 implies the shares have historically moved independently of — and slightly inversely to — the S&P 500, which is unusual for a large-cap industrial and means traditional market-hedging logic does not apply; position sizing should be driven by the stock's own -35.42% drawdown profile rather than index correlation.
Beta
-0.11
-0.11x market volatility
Max Drawdown
-35.4%
Largest decline past year
52-Week Range
$479-$774
Price range past year
Annual Return
-8.4%
Cumulative gain past year
| Period | NOC Return | S&P 500 |
|---|---|---|
| 1m | -10.0% | -2.0% |
| 3m | -4.3% | +1.4% |
| 6m | -27.2% | +15.0% |
| 1y | -8.4% | +15.7% |
| ytd | -9.9% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NOC Fundamental Analysis
Revenue is growing, but only modestly. Most recent quarterly revenue (Q1 2026, ended 2026-03-31) was $9.881 billion, up 4.36% year over year from $9.468 billion in Q1 2025, and the multi-quarter trend shows a clear deceleration from the 13.1% YoY growth implied by Q4 2025's $11.712 billion versus Q4 2024's $10.686 billion. Sequentially, revenue fell from $11.712 billion in Q4 2025 to $9.881 billion in Q1 2026, a normal seasonal pattern but one that leaves the trailing top line dependent on the second half. Segment mix shows Aeronautics Systems as the largest contributor at $3.283 billion, followed by Mission Systems at $2.861 billion, Space Systems at $2.480 billion, and Defense Systems at $1.899 billion; the investment case hinges on Aeronautics (B-21, F-35) and Space scaling faster than the legacy Defense Systems base, and the modest 4.4% consolidated growth suggests that ramp is not yet overwhelming program headwinds elsewhere.
Profitability remains solid but is compressing at the gross line. Q1 2026 net income was $875 million on a 19.84% gross margin and 8.86% net margin, down from Q4 2025's $1.427 billion net income, 19.60% gross margin, and 12.18% net margin, and below Q3 2025's 21.37% gross margin. The trailing valuation data show a 19.81% gross margin, 10.20% operating margin, and 9.97% net margin — healthy absolute levels for a defense prime, where high-single-digit net margins are typical, but the direction of travel matters: gross margin has slipped from the 21.4% area in mid-2025 toward 19.8%, consistent with cost pressure on development programs. ROE of 25.08% looks exceptional, but it is flattered by a leveraged balance sheet and by the low equity base rather than by expanding returns on assets, which sit at a more modest 7.15%.
Balance-sheet and cash-flow quality are the soft spot. Debt-to-equity stands at 1.18x with a current ratio of just 1.09, leaving limited liquidity cushion, and Q1 2026 free cash flow was -$1.823 billion (operating cash flow of -$1.656 billion) driven by a $3.077 billion working-capital outflow — a recurring seasonal pattern that also produced -$1.821 billion in Q1 2025. Trailing-twelve-month free cash flow of $3.305 billion against an $81.8 billion market cap implies an FCF yield of roughly 4.0%, which is respectable but not high enough to fully offset the earnings-quality concerns; the company also returned cash via $333 million of dividends and $68 million of buybacks in the quarter while cash fell from $4.403 billion to $2.090 billion. The key question for investors is whether the H2 cash conversion repeats 2025's pattern (Q4 2025 alone generated $3.235 billion of FCF), which would validate the full-year cash thesis.
Quarterly Revenue
$9.9B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
19.8%
Latest Quarter
Free Cash Flow
$3.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NOC Overvalued?
Because Northrop is solidly profitable — Q1 2026 net income of $875 million and trailing EPS positive — the PE ratio is the appropriate primary metric rather than PS or EV/Sales. The stock trades at 19.57x trailing earnings but only 17.05x forward earnings, a roughly 13% compression that implies the market expects meaningful EPS growth; consensus estimated EPS of $37.82 against the current price of $518.97 indeed implies a forward multiple near 13.7x on that estimate, suggesting either the consensus number is stale or the market is discounting execution risk. The PEG ratio of 7.41 is a red flag, indicating that the trailing earnings growth rate is far too slow to justify even a high-teens PE.
Relative to the broader Industrials/Aerospace & Defense peer set, Northrop screens as a modest premium on book but a discount on cash flow: PB of 4.91x and EV/EBITDA of 13.49x are in line with large-cap prime peers, while the 1.95x PS ratio and 17.20x P/CF are unremarkable for a business with a $55.4 billion consensus revenue base. The 1.58% dividend yield and 30.9% payout ratio are consistent with a mature defense compounder, and the 13.49x EV/EBITDA is not obviously stretched for a franchise with a multi-decade backlog. The valuation debate is therefore less about the multiple level and more about whether the 'E' is reliable — the 7.41 PEG and the gap between trailing and forward PE both signal that the market is skeptical of near-term earnings delivery.
Historically, Northrop's own PE band has been wide: the historical ratios show quarterly PE readings ranging from roughly 13.5x (Q4 2024) and 14.3x (Q4 2025) at the low end to 27.7x (Q1 2026) and 38.4x (Q1 2025) at the high end, with PS oscillating between about 6.5x and 9.8x. At 19.57x trailing PE and 1.95x PS, the stock is in the middle-to-lower portion of its own historical range — cheaper than the Q1 2026 reading of 27.7x PE and 9.81x PS, but not at the trough multiples seen in late 2024. That middle-of-the-band positioning, combined with the stock sitting near 52-week lows, suggests the market has already de-rated the shares substantially; further downside would likely require evidence of structural margin erosion rather than mere multiple compression.
PE
19.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 10x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated by a leveraged balance sheet and volatile cash generation. Debt-to-equity stands at 1.18x with a current ratio of just 1.09, leaving minimal liquidity cushion. Q1 2026 free cash flow was -$1.823 billion, driven by a $3.077 billion working-capital outflow, and cash fell from $4.403 billion to $2.090 billion in the quarter. Gross margin has compressed from 21.37% in Q3 2025 to 19.84% in Q1 2026, reflecting cost pressure on development programs like the B-21 and Sentinel, which could lead to further charges if execution slips. Revenue growth of only 4.36% YoY in Q1 2026, down from 13.1% in Q4 2025, highlights dependence on a few large programs and the risk of earnings volatility if those ramps are delayed.
Market and competitive risks center on valuation compression and sector rotation. At 19.57x trailing PE and 17.05x forward PE, NOC trades at a premium to some peers on book (PB 4.91x) but a discount on cash flow (EV/EBITDA 13.49x), leaving room for further de-rating if earnings disappoint. The beta of -0.11 implies the stock moves independently of the S&P 500, so traditional market hedging does not apply, but this also means NOC is vulnerable to idiosyncratic sentiment shifts. Recent news highlights competitive threats from pure-play space and drone names like Rocket Lab, which is targeting missile defense and Golden Dome, potentially siphoning growth capital and investor attention away from legacy primes. Regulatory headwinds, including rare-earth supply-chain mandates and geopolitical tensions with Iran, add uncertainty, though they also reinforce long-term defense demand.
The worst-case scenario involves a confluence of program charges, continued margin erosion, and a breakdown below the 52-week low of $479.02. If H2 2026 free cash flow fails to replicate 2025's Q4 surge, the full-year cash thesis collapses, potentially triggering analyst downgrades and a re-rating toward the low target of $538 or below. From the current price of $518.97, a drop to the 52-week low of $479.02 represents a decline of approximately 7.7%, but a more severe scenario where the stock revisits its historical trough PE of 13.5x (seen in Q4 2024) on trailing EPS could imply a price near $450, a loss of about 13.3%. The max drawdown of -35.42% from the 52-week high of $774.00 illustrates the stock's capacity for deep declines in adverse conditions.
FAQ
The most severe risk is financial: debt-to-equity of 1.18x and a current ratio of 1.09 leave limited liquidity cushion, and Q1 2026 free cash flow was -$1.823 billion due to a $3.077 billion working-capital outflow. Second, operational risk from margin compression, with gross margin falling from 21.37% in Q3 2025 to 19.84% in Q1 2026, could worsen if program charges materialize. Third, competitive risk from pure-play space and drone companies like Rocket Lab, which are targeting missile defense and Golden Dome, potentially siphoning growth capital. Fourth, macro and regulatory risks, including rare-earth supply-chain mandates and geopolitical tensions, could disrupt production and increase costs. The stock's beta of -0.11 means it does not correlate with the market, so traditional hedging is ineffective.
The 12-month forecast has three scenarios: a bull case (25% probability) targeting $648–$815, driven by successful program execution and H2 free cash flow exceeding $3 billion; a base case (55% probability) targeting $538–$648, assuming modest revenue growth and stable margins; and a bear case (20% probability) targeting $450–$538, triggered by program charges and cash-flow deterioration. The base case is most likely, with the key assumption being that H2 free cash flow reaches $2.5–3.0 billion, sufficient to cover the dividend but not to drive significant multiple expansion. The analyst consensus target of $648.05 aligns with the upper end of the base case, implying 24.9% upside.
NOC appears undervalued on forward earnings, trading at 17.05x forward PE compared to its trailing PE of 19.57x and historical range of 13.5x–38.4x. The PS ratio of 1.95x is also in the middle-to-lower portion of its historical range (6.5x–9.8x), and EV/EBITDA of 13.49x is in line with large-cap prime peers. However, the PEG ratio of 7.41 is a red flag, indicating that trailing earnings growth is too slow to justify even a high-teens PE. The market is pricing in skepticism about near-term earnings delivery, but if the company can execute on its B-21 and space programs, the multiple could expand toward the higher end of its historical band, implying significant upside.
From a risk/reward perspective, NOC offers a compelling upside of 24.9% to the analyst consensus target of $648.05, but the downside risk to the 52-week low of $479.02 is about 7.7%, and a more severe scenario could see a 13.3% decline to $450. The stock trades at 17.05x forward earnings, near the low end of its historical range, which limits further multiple compression. However, the company faces near-term headwinds including a 4.36% revenue growth rate, gross margin compression to 19.84%, and negative Q1 free cash flow of -$1.823 billion. It is a good buy for long-term investors with a 2-3 year horizon who believe in the defense spending cycle and can tolerate volatility, but short-term traders may find better opportunities elsewhere given the accelerating downtrend.
NOC is better suited for long-term investment given its strategic franchise, multi-decade backlog, and 1.58% dividend yield, but the current downtrend and negative momentum make short-term trading risky. The stock has a beta of -0.11, meaning it does not move with the market, and its max drawdown of -35.42% over the past year illustrates high volatility. Earnings visibility is moderate, with analyst EPS estimates ranging from $37.20 to $38.67 for the year, but quarterly cash flow is highly seasonal and volatile. A minimum holding period of 2-3 years is recommended to ride out program cycles and allow the B-21 and space ramps to mature, at which point the valuation discount could narrow.